Rapid Oral Abstract Presentations | Kidney Cancer Research Summit 2025

This KCRS25 Rapid Oral Abstract session features concise, high-impact presentations on novel clinical trials and research studies in kidney cancer. Topics include quality-of-life analysis in advanced RCC, metastasis-directed radiotherapy without systemic therapy, microbiome checkpoints, and more.

Moderators: Sumanta Pal (City of Hope Comprehensive Cancer Center), Kelly Fitzgerald (University of California, San Francisco)

Quality-Adjusted Time without Symptoms or Toxicity (QTWiST) Analysis of Belzutifan Versus Everolimus in Previously Treated Advanced RCC: LITESPARK-005 (LS-005) — Thomas Powles (Barts Cancer Center)

Exploring Health-Related Quality of Life Across the Disease Spectrum in Renal Cell Carcinoma: A Conceptual Domain Analysis — Koral Shah (City of Hope Comprehensive Cancer Center)

Phase 2 Trial of Metastasis-Directed Radiotherapy without Systemic Therapy (MRWS) for Oligometastatic Clear Cell RCC and Investigation of Circulating Tumor DNA (ctDNA) — Chad Tang (MD Anderson Cancer Center)

The Actionable Microbial Gut Checkpoint MAdCAM-1 in Patients with Advanced RCC — Carolina Alves Costa Silva (Institut Gustave Roussy)

Characterizing Carbonic Anhydrase 9 and HIF-2α RNA Expression in Clear Cell RCC — Yu-Wei Chen (University of California, San Diego)

Influence of Sex on Immunosurveillance and Metastatic Tropism in Novel Mouse Models of Clear Cell RCC — Doris Zheng (Memorial Sloan Kettering Cancer Center)

Evaluating Global Disparities in Clinical Trial Availability for Renal Cell Carcinoma — Ruchi Agarwal (University of Pennsylvania)

Investigating the Mechanisms of Neoadjuvant Olaparib and Cediranib in Renal Cancer: Results of Arms 1 to 3 of the WIRE Clinical Trial — James Jones (University of Cambridge)

Real-World Evidence Shows No Survival Advantage with Contemporary First-Line Strategies in Papillary RCC: A Call for Randomized Trials — Miguel Zugman (City of Hope Comprehensive Cancer Center)